Bupropion lowers weight in some people, and no regulator has approved it for that. The antidepressant's US label is written for depression and seasonal affective disorder. Its weight table records the effect as a side note, and the one approved product that uses bupropion for weight also uses naltrexone. This page reports what the label and the trials record, dated, and says where the record stops.
Read on 9 November 2026 from the Wellbutrin XL label (Bausch Health, DailyMed set a435da9d, revised November 2025), the label's own trial tables, and the 2026 trial cited below.
What the label is for
The Wellbutrin XL label lists two indications: major depressive disorder and the prevention of seasonal affective disorder. Weight loss is not among them, and the label contains no weight-management claim. Bupropion is an aminoketone antidepressant.
The same molecule is sold as Zyban for smoking cessation, and it is one half of Contrave, the long-term weight medicine approved on 10 September 2014. Those are different labels with different trials and different dose limits.
What the weight table records
The weight table is the one place the label reports weight. It counts people whose weight changed by 5 pounds or more in the short-term depression trials of the sustained-release tablet:
| Arm | Trial size | Lost 5 lb or more | Gained 5 lb or more |
|---|---|---|---|
| Bupropion sustained-release 300 mg a day | 339 | 14% | 3% |
| Bupropion sustained-release 400 mg a day | 112 | 19% | 2% |
| Placebo | 347 | 6% | 4% |
The label says there was "a dose-related decrease in body weight." In the three short-term seasonal affective disorder trials of the extended-release tablet, 23% of people on bupropion lost 5 pounds or more, against 11% on placebo.
What these figures are not. They are counts of people crossing a 5-pound threshold, not mean weight changes, and they are not measured over a long period. The depression trials were not designed to test weight, so no population was selected for it, and no mean loss is printed in the table. Read them as a record of an observed side effect, not as a weight-loss result.
The 2026 trial that measured weight on bupropion alone
A randomised trial published in Drug and Alcohol Dependence on 8 October 2026 (Rose et al.; 60 adults per arm, weeks 2–8 of a switch to e-cigarettes) recorded weight in three arms. Weight gain occurred on bupropion alone and on placebo; weight loss was observed on bupropion plus zonisamide. The authors describe the weight result as exploratory. The trial was not designed to measure weight, and its groups are small, so it cannot establish a weight effect for bupropion on its own. It is recorded here because it is the most recent randomised measurement of weight on bupropion alone that we have opened.
Where the approved weight data sit
The approved long-term weight data for this molecule are in Contrave, which pairs bupropion 90 mg with naltrexone 8 mg. In the label's four 56-week trials, weight fell 3.7% to 8.1% on the combination against 1.3% to 4.9% on placebo; the Contrave page sets out each trial, and almost half of each group withdrew. The combination's figures are not evidence about bupropion alone, and this page does not extend them to it; the same holds for the other ingredient, whose separate trial record is set out on naltrexone for weight loss.
Safety the label prints
- Suicidal thoughts and behaviour. The Wellbutrin XL label carries a boxed warning on suicidal thoughts and behaviours, set out in the label's opening warning section.
- Seizure. The label states that seizure risk is dose-related, that the dose should not exceed 300 mg once daily, and that the dose should be increased gradually. The label's own text is the reference for any reader who is taking the drug or considering it.
Those are the label's warnings as printed. They are the reason the drug is taken under a prescriber's direction, not a reason to start or stop it, and any question about its use for weight belongs with the prescribing clinician.
What is not established
- No trial has tested bupropion alone as a weight-loss treatment in the population the label covers, in the form the label describes.
- No label gives a weight endpoint for bupropion, so no regulator has judged that effect.
- The 2026 weight finding comes from one small exploratory trial in people who smoke, not in people with obesity.
Counts such as these are where a reader should stop and ask a clinician — whether an antidepressant is suitable at all, given the depression, seizure and suicidality warnings, is a medical decision that this page does not and cannot make.